Clinical experience with infliximab therapy in 100 patients with Crohn’s disease

摘要: Abstract OBJECTIVE: The aim of this study was to assess our clinical experience with infliximab, a monoclonal antitumor necrosis factor antibody, following its approval for treatment refractory Crohn’s disease (CD). METHODS: We followed 100 consecutive patients CD (53 women and 47 men; mean age, 41 yr) who received total 233 infliximab (5 mg/kg) infusions. Adverse events were noted response assessed every 2 wk 6 months after each infusion using the Harvey Bradshaw Index (HBI) active disease, Perianal Disease Activity (PDAI) fistulous steroid withdrawal rates steroid-sparing efficacy. RESULTS: Indications therapy (n = 57), perianal 33), dependency 10). Significant reactions occurred in 16 (6.9% infusions) including anaphylactic shock one patient. Fourteen experienced infectious adverse events, 13 whom on concurrent steroids. Sixty percent ≥50% HBI reduction at wk; duration response, 8.2 wk. Three 26 first-time nonresponders (12%) responded second infusion. Sixty-nine >50% their PDAI 10.9 Four 10 steroid-dependent (40%) discontinued therapy, recommenced 24 CONCLUSIONS: Our mirror efficacy reported controlled trials disease. Steroid-sparing seen 40% patients. Concurrent steroids did not reduce risk significant (6.9%), but increase infections.